研究概要
CD38与CD8+ TRM上耗竭标志物的共表达,奠定了其作为T细胞耗竭关键标志物以及恢复HCC中细胞毒性T细胞功能的潜在治疗靶点的作用。
研究思路结论见上方概要
背景
尽管肝细胞癌(HCC)免疫治疗近期取得了进展,但总体应答率不高,这凸显出需要更好地理解HCC的肿瘤微环境(TME)。我们此前已表明,CD38广泛表达于肿瘤浸润白细胞(TILs),主要表达于CD3+ T细胞和单核细胞。然而,其在HCC TME中的具体作用仍不清楚。
方法
在本研究中,我们使用飞行时间流式细胞术(CyTOF)、分选T细胞的bulk RNA测序以及单细胞RNA(scRNA)测序,探究HCC样本中CD38的表达及其与T细胞耗竭的相关性。我们还采用多重免疫组化(mIHC)验证我们的发现。
结果
通过CyTOF分析,我们比较了TIL、非肿瘤组织浸润白细胞(NIL)和外周血单个核细胞(PBMC)中表达CD38的白细胞的免疫组成。我们确定CD8+ T细胞是TIL中主要的表达CD38的T细胞,并发现TIL中CD8+ TRM的CD38表达显著高于NIL。此外,通过对从HCC肿瘤中分选出的CD8+ TRM进行转录组分析,我们观察到与来自PBMC的循环记忆CD8 T细胞相比,CD38以及T细胞耗竭基因(包括PDCD1和CTLA4)的表达更高。scRNA测序验证了这一点,揭示HCC肿瘤T细胞中CD38与PDCD1、CTLA4和ITGAE(CD103)的共表达。通过mIHC在HCC FFPE组织上进一步证明了CD8+ T细胞上CD38和PD-1的蛋白共表达,将CD38标记为HCC中的T细胞共耗竭标志物。最后,CD38+ PD-1+ CD8+ T细胞和CD38+ PD-1+ TRM的较高比例与HCC较高的组织病理学分级显著相关,表明其在疾病侵袭性中的作用。
展开英文摘要原文
INTRODUCTION: Despite recent advances in immunotherapy for hepatocellular carcinoma (HCC), the overall modest response rate underscores the need for a better understanding of the tumor microenvironment (TME) of HCC. We have previously shown that CD38 is widely expressed on tumor-infiltrating leukocytes (TILs), predominantly on CD3 + T cells and monocytes. However, its specific role in the HCC TME remains unclear.
METHODS: In this current study, we used cytometry time-of-flight (CyTOF), bulk RNA sequencing on sorted T cells, and single-cell RNA (scRNA) sequencing to interrogate expression of CD38 and its correlation with T cell exhaustion in HCC samples. We also employed multiplex immunohistochemistry (mIHC) for validating our findings.
RESULTS: From CyTOF analysis, we compared the immune composition of CD38-expressing leukocytes in TILs, non-tumor tissue-infiltrating leukocytes (NIL), and peripheral blood mononuclear cells (PBMC). We identified CD8 + T cells as the dominant CD38-expressing TILs and found that CD38 expression was significantly higher in CD8 + T RM in TILs than in NILs. Furthermore, through transcriptomic analysis on sorted CD8 + T RM from HCC tumors, we observed a higher expression of CD38 along with T cell exhaustion genes, including PDCD1 and CTLA4, compared to the circulating memory CD8 T cells from PBMC. This was validated by scRNA sequencing that revealed co-expression of CD38 with PDCD1, CTLA4, and ITGAE (CD103) in T cells from HCC tumors. The protein co-expression of CD38 and PD-1 on CD8 + T cells was further demonstrated by mIHC on HCC FFPE tissues, marking CD38 as a T cell co-exhaustion marker in HCC. Lastly, the higher proportions of CD38 + PD-1 + CD8 + T cells and CD38 + PD-1 + T RM were significantly associated with the higher histopathological grades of HCC, indicating its role in the aggressiveness of the disease.
CONCLUSION: Taken together, the concurrent expression of CD38 with exhaustion markers on CD8 + T RM underpins its role as a key marker of T cell exhaustion and a potential therapeutic target for restoring cytotoxic T cell function in HCC.
论文信息
- 作者
- Reolo MJY、Otsuka M、Seow JJW、Lee J、Lee YH、Nguyen PHD、Lim CJ、Wasser M
- 单位
- Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.Singapore
- 文献类型
- 非美国政府资助研究
- 期刊
- Frontiers in immunology2023